Compare ANTX & RFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANTX | RFAM |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 137.1M |
| IPO Year | 2022 | 2026 |
| Metric | ANTX | RFAM |
|---|---|---|
| Price | $4.60 | $9.87 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 214.1K | 15.0K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $9.77 |
| 52 Week High | $6.91 | $9.94 |
| Indicator | ANTX | RFAM |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 55.35 |
| Support Level | $1.06 | $9.81 |
| Resistance Level | $5.14 | $9.90 |
| Average True Range (ATR) | 0.42 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 54.07 | 50.00 |
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
RF Acquisition Corp III is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.